[Advances in prostate-specific membrane antigen targeted therapies for prostate cancer].
Prostate-specific membrane antigen (PSMA) is a type II integral membrane glycoprotein, specifically expressed in prostatic epithelial cells and strongly upregulated in prostate cancer. PSMA is also present in the neovasculature of other solid tumors. These findings have spurred the development of PSMA-targeted therapies for prostate cancer, including immunotherapy, radioimmunotherapy, chemotherapy and gene therapy, and initiated the clinical trials of the first-generation products. However, general clinical application of these therapies still requires extensive clinical studies to test their clinical safety, stability and efficacy.
Wang
Wei
W
Department of Urology, Institute of Urology and Nephrology, The First Affiliated Hospital, Guangxi Medical University, Nanning, Guangxi 530021, China. wangwei_gxmu@163.com
Mo
Zeng-Nan
ZN
D000954:Antigens, Surface; D015316:Genetic Therapy; D043425:Glutamate Carboxypeptidase II; D006801:Humans; D007167:Immunotherapy; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000628:therapy; D016499:Radioimmunotherapy
D000954:Antigens, Surface; C473848:FOLH1 protein, human; D043425:Glutamate Carboxypeptidase II